Top 5 Sodium Ferric Gluconate Options in the UK for 2026
Published on Monday, 26 January 2026
Sodium Ferric Gluconate is an intravenous iron therapy used to treat moderate to severe iron deficiency and iron deficiency anemia when oral iron is ineffective or not tolerated. In the UK market it appeals to clinicians and patients for its rapid iron repletion, predictable dosing, and usually lower gastrointestinal side effects compared with oral supplements. Buyers in 2026 prioritise safety records, clear dosing protocols, NHS availability, cost-effectiveness, and brand support for clinic-based administration. Clinicians also consider formulation stability, infusion times, and published clinical experience in specific groups such as chronic kidney disease, dialysis patients, perioperative care and those with inflammatory bowel disease.
Top Picks Summary
Ferrlecit
Ferrlecit (sodium ferric gluconate complex in sucrose) is a market-leading intravenous iron formulation with long-standing regulatory approvals and an established safety record, making it a common choice for dialysis and chronic kidney disease-related iron therapy. Compared with the other products on this list it typically commands a premium price but offers predictable supply, manufacturer support, and brand familiarity; technically it is comparable to other ferric gluconate products but often favored where continuity and post-market support are prioritized.
£140 – £220
Sodium Ferric Gluconate Complex in Sucrose Injection
The generic sodium ferric gluconate complex in sucrose injection provides a cost-effective alternative to branded ferric gluconate therapies and is widely used where formulary savings are important. Technically equivalent in active composition to Ferrlecit and other listed ferric gluconate products, generics typically offer lower acquisition costs and broader purchasing flexibility, though they can vary by supplier in packaging, supply reliability, and post-market services.
Ferric Gluconate Vifor
Ferric Gluconate from Vifor leverages the company’s global haemato-renal specialty focus and distribution network to be a market leader in many international regions. It competes with U.S. branded options by combining broad regulatory registrations and competitive regional pricing, and its technical advantage comes from extensive pharmacovigilance and integrated patient support programs that can reduce indirect treatment costs.
£150 – £260
Nulecit
Nulecit is positioned as a value-oriented ferric gluconate product aimed at cost-sensitive markets and regional hospital procurement. Delivering the same active sodium ferric gluconate complex as Ferrlecit and other brands, Nulecit’s main advantage is lower acquisition cost and flexible local supply, though it may have more limited global regulatory approvals and less extensive manufacturer support compared with large international brands.
£60 – £120
Ferrlecit IV Injection
Ferrlecit IV Injection represents the branded intravenous presentation of ferric gluconate, emphasizing established IV dosing protocols and clinician familiarity. It offers the same active complex as other products listed but typically at higher cost; its strengths lie in consistent supply, product-specific administration guidance, and the service elements associated with a recognizable branded therapy.
What the research says about intravenous sodium ferric gluconate
Clinical studies and observational series show that intravenous sodium ferric gluconate can quickly raise hemoglobin and replenish iron stores, making it a useful option when oral therapy fails or rapid correction is needed. Research in dialysis and chronic kidney disease populations is particularly well established, supporting improved iron indices and reduced need for blood transfusion in some settings. Safety monitoring commonly focuses on ferritin, transferrin saturation (TSAT) and infusion reactions, and many studies report a favourable tolerability profile when administered in clinical settings.
How it works: sodium ferric gluconate is an iron core complexed with gluconate that releases bioavailable iron once processed by the reticuloendothelial system.
Clinical outcomes: trials and registries show consistent rises in hemoglobin, ferritin and TSAT; benefits are most clear when oral iron is inadequate or too slow.
Safety and monitoring: common adverse effects include transient hypotension, nausea and infusion-site reactions; routine monitoring of hemoglobin, ferritin and TSAT is recommended.
Comparisons with oral iron: IV sodium ferric gluconate provides faster repletion and avoids gastrointestinal side effects that limit oral therapy adherence.
Use cases supported by evidence: chronic kidney disease (including dialysis), perioperative anaemia correction, heavy menstrual bleeding and inflammatory bowel disease where absorption is impaired.
Regulatory context: products used in the UK are subject to MHRA oversight and are typically available through hospital formularies and the NHS where indicated.
Frequently Asked Questions
Which sodium ferric gluconate is best for dialysis patients?
Ferrlecit is the recommended choice for dialysis and chronic kidney disease patients due to its long-standing regulatory approvals and established safety record. It holds an average rating of 4.5 and is specifically designed for rapid iron repletion in clinical settings.
What is the average rating of the generic sodium ferric gluconate?
The generic Sodium Ferric Gluconate Complex in Sucrose Injection has an average rating of 4.3. It is technically equivalent in active composition to branded options and provides a reliable, cost-effective alternative for elemental iron replacement.
Is Ferric Gluconate Vifor suitable for hospital use in the UK?
Ferric Gluconate Vifor is specifically supplied by a major UK and EU haematinics manufacturer for hospital use. It features formulations and pack sizes tailored for dialysis units and maintains a 4.4 average rating for its consistent iron delivery.
Does Ferrlecit require monitoring during intravenous iron therapy?
Ferrlecit requires monitoring for hypersensitivity and post-infusion iron indices to ensure patient safety. As a branded formulation, it is widely used for iron-deficiency and chronic kidney disease patients, offering a well-characterised safety profile for those undergoing intravenous iron repletion.
Conclusion
This 2026 UK overview highlights five leading sodium ferric gluconate options: Ferrlecit, Sodium Ferric Gluconate Complex in Sucrose Injection, Ferric Gluconate Vifor, Nulecit, and Ferrlecit IV Injection. Each product has a place depending on local availability, dosing preferences and NHS formulary decisions. For most UK clinics and patients seeking a well established balance of efficacy, safety and service support, Ferrlecit is often the preferred choice due to its long clinical track record and familiar dosing pathways. We hope you found what you were looking for; you can refine or expand your search using the site search to compare dosing, availability and patient support options for each product.